{"product_id":"understanding-lyme-disease-a-complete-guide-to-diagnosis-and-treatment","title":"Understanding Lyme Disease: A Complete Guide to Diagnosis and Treatment","description":"\u003cp\u003eLyme borreliosis (Lyme disease) is a complex, multi-organ infection caused by Borrelia bacteria transmitted through tick bites. This comprehensive guideline from the German Borreliosis Society provides detailed recommendations for diagnosing and treating both early and chronic forms of the disease, emphasizing that up to 50% of patients do not recall a tick bite and that seronegativity does not rule out infection. The guidelines highlight the importance of early antibiotic treatment, the limitations of standard laboratory testing, and the value of cellular diagnostic methods like the lymphocyte transformation test (LTT). Treatment recommendations differ significantly from other specialist societies, particularly regarding long-term antibiotic therapy for chronic manifestations.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Lyme Disease: A Complete Guide to Diagnosis and Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Is Lyme Borreliosis?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#essential-features\"\u003eEssential Features of Lyme Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnostic-strategy\"\u003eDiagnostic Strategy in Daily Practice\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#tick-bite\"\u003eWhat to Do After a Recent Tick Bite\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#erythema-migrans\"\u003eErythema Migrans and Lymphocytoma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#early-stage\"\u003eEarly Stage Without Erythema Migrans\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#chronic-stage\"\u003eChronic Lyme Borreliosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#occupational\"\u003eOccupational Disease and Accident Insurance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#chronic-symptoms\"\u003eSymptoms of Chronic Lyme Borreliosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lab-diagnostics\"\u003eLaboratory Diagnostics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#direct-identification\"\u003eDirect Identification of Borrelia\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#serology\"\u003eBorrelia Serology (Antibody Testing)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#csf\"\u003eExamination of Cerebrospinal Fluid (CSF)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ltt\"\u003eLymphocyte Transformation Test (LTT)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cd57\"\u003eCD57+ NK Cells\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#co-infections\"\u003eCo-infections\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#antibiotic-treatment\"\u003eAntibiotic Treatment of Lyme Borreliosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#unsuitable-antibiotics\"\u003eUnsuitable Antibiotics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#suitable-antibiotics\"\u003eSuitable Antibiotics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#monotherapy\"\u003eMonotherapy Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#combined-therapy\"\u003eCombined Therapy Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prevention\"\u003ePrevention Strategies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of Current Knowledge\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eUp to 50% of Lyme patients recall no tick bite; absence of rash does not rule out infection.\u003c\/li\u003e\n\u003cli\u003eNegative antibody tests do not exclude Lyme disease, especially after early antibiotic treatment.\u003c\/li\u003e\n\u003cli\u003eLymphocyte transformation test (LTT) can indicate active infection when serology is inconclusive.\u003c\/li\u003e\n\u003cli\u003eEarly antibiotic treatment within 4 weeks of infection improves outcomes significantly.\u003c\/li\u003e\n\u003cli\u003eChronic Lyme disease may cause fatigue, neurological, joint, and skin symptoms lasting over 6 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Is Lyme Borreliosis?\u003c\/h2\u003e\n\n\u003cp\u003eLyme borreliosis was first identified as a distinct disease in 1975 by Steere and colleagues, and the causative agent was discovered in 1981 by Willi Burgdorfer. Despite intensive research since then, there remains an inadequate scientific basis for the diagnosis and treatment of this condition, especially for chronic forms where evidence-based studies are lacking.\u003c\/p\u003e\n\n\u003cp\u003eThe disease occurs throughout Europe, and infection typically happens in the countryside, in one's own garden, or through contact with domestic and wild animals. Lyme borreliosis is classified in the ICD-10-GM Diagnosis Code under A 69.2 \"Lyme disease, Erythema chronicum migrans due to B. burgdorferi\" and under M 01.2 \"Arthritis in Lyme Disease.\"\u003c\/p\u003e\n\n\u003cp\u003eThe earlier classification of the disease into three stages (Stage I with erythema migrans, Stage II with early organ manifestations, and Stage III with late manifestations) is now considered outdated because clinical signs of the various stages overlap. Today, doctors prefer to classify the disease into early and late manifestations, with \"chronic Lyme borreliosis\" being equivalent to what was formerly called Stage III.\u003c\/p\u003e\n\n\u003ch2 id=\"essential-features\"\u003eEssential Features of Lyme Disease\u003c\/h2\u003e\n\n\u003cp\u003eLyme borreliosis is known as a multiorgan disease because it can affect many different organs and systems in the body. This creates a wide range of differential diagnoses for the often numerous manifestations of the disease.\u003c\/p\u003e\n\n\u003cp\u003eThe essential features of Lyme borreliosis include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eErythema migrans (EM) — the characteristic \"bull's eye\" rash, though this is not inevitable\u003c\/li\u003e\n  \u003cli\u003eLymphocytoma (a reddened nodular swelling) and acrodermatitis chronica atrophicans (a skin condition in late stages)\u003c\/li\u003e\n  \u003cli\u003eFlu-like condition in the early stage, even without EM, as a sign of pathogen dissemination\u003c\/li\u003e\n  \u003cli\u003eUsually acute manifestations in various organ and tissue systems with a wide variety of symptoms\u003c\/li\u003e\n  \u003cli\u003eChronic fatigue and rapid fatiguability, an episodic disease course with a strong feeling of illness, and symptoms that appear in different places\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCharacteristic of the late manifestations are chronic fatigue, rapid fatiguability, and symptoms that appear in different locations throughout the body. Many different organ-specific symptoms may also be present, which we will discuss in detail below.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnostic-strategy\"\u003eDiagnostic Strategy in Daily Practice\u003c\/h2\u003e\n\n\u003cp\u003eIn daily medical practice, doctors encounter several distinct situations when dealing with potential Lyme borreliosis. These include a recent tick bite, erythema migrans and lymphocytoma, early stage without erythema migrans, and chronic stage. Each situation requires a different diagnostic approach.\u003c\/p\u003e\n\n\u003cp\u003eOne of the most important facts to understand is that up to 50% of borreliosis patients deny having suffered a tick bite when their history is taken. This means that a negative history of tick bites does not rule out Lyme borreliosis. The longest latency period before the occurrence of symptoms of the disease was documented at 8 years.\u003c\/p\u003e\n\n\u003ch2 id=\"tick-bite\"\u003eWhat to Do After a Recent Tick Bite\u003c\/h2\u003e\n\n\u003cp\u003eIf you have recently been bitten by a tick, the guidelines recommend observing the site of the bite for 4–6 weeks. If any reddening (erythema) occurs, you should consult a doctor immediately. It also makes sense to examine the tick itself for Borrelia using PCR testing, though a negative PCR result does not entirely rule out the infectiousness of the tick.\u003c\/p\u003e\n\n\u003cp\u003eSerological testing (blood tests for antibodies) is recommended to confirm insurance claims, for patients with a history of Lyme borreliosis, and if it is planned to monitor the course of the disease. If antibodies against Borrelia are found in the blood at a check-up examination 6 weeks after a tick bite, infection has occurred. This can be proven only with a pair of serum samples taken at different times.\u003c\/p\u003e\n\n\u003cp\u003ePatients themselves should keep a diary and record any cutaneous changes photographically. If the tick is still present, it is advisable to keep it for later testing for Borrelia by PCR.\u003c\/p\u003e\n\n\u003ch2 id=\"erythema-migrans\"\u003eErythema Migrans and Lymphocytoma\u003c\/h2\u003e\n\n\u003cp\u003eErythema migrans is considered evidential for Lyme borreliosis. The conclusion is clear: immediate antibiotic treatment is required. The earlier the antibiotic treatment is started, the better the infection can be controlled. Therapeutic success is distinctly poorer even 4 weeks after the start of infection.\u003c\/p\u003e\n\n\u003cp\u003eBorrelia-specific antibodies do not appear until 2–6 weeks after the start of infection. Antibiotic treatment at an early stage can prevent the development of antibodies, meaning no seroconversion takes place. Therefore, seronegativity (negative antibody test) following early antibiotic treatment does not rule out Lyme borreliosis in any way.\u003c\/p\u003e\n\n\u003cp\u003eIf there is a corresponding history of tick exposure and a reddened nodular swelling is found — for example on the nipple, skin of the scrotum, bends of joints, and in children often on the external ear — this may be a lymphocytoma. A Borrelia lymphocytoma is evidential of Lyme borreliosis just as erythema migrans is, taking into consideration the differential diagnosis. This type of lymphocytoma is usually caused by Borrelia afzelii and sometimes forms in the centre of an erythema migrans in the region of the original tick bite. Borrelia can be isolated from all areas of an erythema migrans and of a Borrelia lymphocytoma.\u003c\/p\u003e\n\n\u003ch2 id=\"early-stage\"\u003eEarly Stage Without Erythema Migrans\u003c\/h2\u003e\n\n\u003cp\u003eIn up to 50% of cases, no erythema migrans is observed in the early stage of Lyme borreliosis. In the absence of EM, the diagnosis is based on several criteria: the circumstances of the illness (time spent in one's own garden and in the countryside, tick bite), a thorough physical examination with inspection of the skin in search for EM (including those possibly with diameters less than 5 cm) and lymphocytomas, and laboratory diagnostic tests.\u003c\/p\u003e\n\n\u003cp\u003eFirst manifestations of Lyme borreliosis sometimes do not occur for weeks to years after the start of infection. If appropriate symptoms are present, especially if tick bites are mentioned during history-taking, or if there is a high risk of infection, Lyme borreliosis must always be considered in the differential diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eThe following may occur in the early stage:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTransient migratory arthritis, arthralgia (joint pain) and myalgia (muscle pain)\u003c\/li\u003e\n  \u003cli\u003eBursitis (inflammation of bursae) and enthesitis (inflammation at tendon attachment sites)\u003c\/li\u003e\n  \u003cli\u003eHeadaches\u003c\/li\u003e\n  \u003cli\u003eRadicular pain syndromes (known as Bannwarth's syndrome)\u003c\/li\u003e\n  \u003cli\u003eCranial nerve symptoms, especially facial nerve paresis (weakness or paralysis)\u003c\/li\u003e\n  \u003cli\u003eSensitivity disturbances (numbness, tingling)\u003c\/li\u003e\n  \u003cli\u003eCardiac dysrhythmias, stimulus formation and stimulus conduction disorders (heart rhythm problems)\u003c\/li\u003e\n  \u003cli\u003eOcular symptoms, such as double vision\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"chronic-stage\"\u003eChronic Lyme Borreliosis\u003c\/h2\u003e\n\n\u003cp\u003eThe time differentiation between the early and late stages is somewhat arbitrary. Disease manifestations of Lyme borreliosis which occur more than 6 months after the start of infection are designated in this guideline as late manifestations or as chronic.\u003c\/p\u003e\n\n\u003cp\u003eLyme borreliosis can lead to numerous symptoms in the chronic stage. The following are particularly frequent:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFatigue (exhaustion, a chronic feeling of illness)\u003c\/li\u003e\n  \u003cli\u003eEncephalopathy (impaired cerebral function)\u003c\/li\u003e\n  \u003cli\u003eMuscular and skeletal symptoms\u003c\/li\u003e\n  \u003cli\u003eNeurological symptoms, including polyneuropathy (nerve damage)\u003c\/li\u003e\n  \u003cli\u003eGastrointestinal symptoms\u003c\/li\u003e\n  \u003cli\u003eUrogenital symptoms\u003c\/li\u003e\n  \u003cli\u003eOcular symptoms\u003c\/li\u003e\n  \u003cli\u003eCutaneous (skin) symptoms\u003c\/li\u003e\n  \u003cli\u003eHeart diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA cutaneous manifestation indicative of the illness in its late stage is acrodermatitis chronica atrophicans (ACA), a skin condition characterized by thinning and discoloration of the skin. Chronic polyneuropathy, which often accompanies ACA, is also seen as a typical manifestation of the illness in its late stage.\u003c\/p\u003e\n\n\u003ch2 id=\"occupational\"\u003eOccupational Disease and Accident Insurance\u003c\/h2\u003e\n\n\u003cp\u003eLyme borreliosis is classed as an occupational disease according to No. 3102 in Annex 1 to the Occupational Diseases Regulation in Germany. The only deciding factor is whether the tick bite (the infection) occurred in the course of one's work. For certain occupational groups at high risk of infection — including farmers, forestry workers, and veterinarians — a relationship between the tick bite and the disease is generally accepted as causal. For other occupational groups, this causal relationship must be demonstrated by the person affected.\u003c\/p\u003e\n\n\u003cp\u003eTherefore, when a tick bite occurs during work and manifestations of the illness subsequently appear, the attending physician must carefully document the history, the examination findings, and the laboratory results. The same applies to a tick bite suffered by individuals who have taken out relevant accident insurance.\u003c\/p\u003e\n\n\u003cp\u003eIn the case of a tick bite during work or for those with accident insurance, a serological test for Borrelia should be performed as soon as possible after exposure, and the test system should be documented. Seroconversion, a significant rise in titre, or an increase in the bands in the immunoblot in the course of four to six weeks must be regarded as proof of a Borrelia infection.\u003c\/p\u003e\n\n\u003ch2 id=\"chronic-symptoms\"\u003eSymptoms of Chronic Lyme Borreliosis\u003c\/h2\u003e\n\n\u003cp\u003eThe symptoms of chronic Lyme borreliosis develop either seamlessly from the early stage, or only after a symptomless interval of months to years, or may indeed develop from the outset as chronic Lyme borreliosis without patients being aware of an early stage. The conclusion to draw from this is that chronic Lyme borreliosis may exist even in the absence of a history of tick bite and erythema migrans, if the circumstances of the illness, its manifestations, and the differential diagnostic analysis make this a reasonable assumption.\u003c\/p\u003e\n\n\u003cp\u003eInflammation of the knee joint (gonitis), after other causes have been excluded by differential diagnosis, is evidential of the late phase of chronic Lyme borreliosis.\u003c\/p\u003e\n\n\u003cp\u003eThe spread of Borrelia in the body leads to multiorgan or systemic disease with an exceptionally wide variety of possible manifestations. Beyond the most common symptoms mentioned above, the disease can affect:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNeurological and mental health: including cognitive difficulties, mood changes, and various neurological syndromes\u003c\/li\u003e\n  \u003cli\u003eHormonal, vegetative and immunological manifestations: affecting the endocrine system and immune response\u003c\/li\u003e\n  \u003cli\u003eMuscular and skeletal systems: including arthritis and muscle pain\u003c\/li\u003e\n  \u003cli\u003eCutaneous manifestations: various skin conditions beyond erythema migrans\u003c\/li\u003e\n  \u003cli\u003eCardiovascular symptoms: including heart rhythm disturbances and inflammation\u003c\/li\u003e\n  \u003cli\u003eOcular manifestations: affecting vision and eye structures\u003c\/li\u003e\n  \u003cli\u003eManifestations during pregnancy: which require special attention\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"lab-diagnostics\"\u003eLaboratory Diagnostics\u003c\/h2\u003e\n\n\u003cp\u003eLyme borreliosis-related laboratory diagnostic tests for Borrelia infection are indicated if there are symptoms or clinical findings present which are consistent with Lyme borreliosis. However, serological monitoring tests to assess the success of treatment are not useful in chronic Lyme borreliosis. The success of treatment must be assessed clinically.\u003c\/p\u003e\n\n\u003ch2 id=\"direct-identification\"\u003eDirect Identification of Borrelia\u003c\/h2\u003e\n\n\u003cp\u003eLyme borreliosis is an infectious disease. Applying strict scientific criteria — especially in scientific studies — only the detection of Borrelia in culture with identification of the causative agent by PCR is considered proof of a Borrelia infection.\u003c\/p\u003e\n\n\u003cp\u003eThe identification of Borrelia DNA by a polymerase chain reaction (PCR for Borrelia) is also of major relevance. Although the sensitivity of this identification technique is poor, especially in the late manifestations of Lyme borreliosis, tests should nevertheless be conducted to identify the causative agent. This includes testing skin biopsy specimens when suspicious cutaneous changes are present, other biopsy specimens and puncture specimens (for example in cases of joint inflammation), and cerebrospinal fluid (CSF) in cases of acute neuroborreliosis. Importantly, negative results do not rule out Lyme borreliosis.\u003c\/p\u003e\n\n\u003ch2 id=\"serology\"\u003eBorrelia Serology (Antibody Testing)\u003c\/h2\u003e\n\n\u003cp\u003eBorrelia serology is the basic diagnostic tool to answer the question of whether a Borrelia infection might be present. However, the test systems on the market (ELISA and immunoblotting) are not standardised, meaning findings from different laboratories can be compared to only a limited degree.\u003c\/p\u003e\n\n\u003cp\u003eTesting for the presence of Borrelia-specific antibodies is possible only with an immunoblot. If a Borrelia infection is suspected, an IgG and IgM immunoblot for Borrelia should be carried out in all cases. The request note to the laboratory must therefore state: \"Borrelia serology inc. immunoblotting for Borrelia.\" In addition, the clinical diagnosis or suspected diagnosis should be given as Lyme borreliosis.\u003c\/p\u003e\n\n\u003cp\u003eThe procedure recommended by the Robert Koch Institute (RKI) and prescribed by the Association of Health Insurance Funds — to conduct immunoblotting as a confirmatory test only if the ELISA is abnormal (a process known as stepwise diagnostics) — must be rejected because this leads to serologically false-negative results in up to a further 15% of patients. The reason for this is that the antigen spectrum present in the immunoblot is usually not identical to that included in the ELISA exploratory test. An ELISA and an immunoblot for Borrelia are two different test methods which can yield differing results in the individual case, even though they correlate with each other to a high degree.\u003c\/p\u003e\n\n\u003cp\u003eThe immunoblot detects antibodies against specific Borrelia antigens, each with different diagnostic significance:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep14, p18:\u003c\/strong\u003e High specificity, mainly in cases of B. afzelii\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep21 (DbpA):\u003c\/strong\u003e High specificity, binds to decorin protein on host cells, especially in the skin\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep22-25 (OspC):\u003c\/strong\u003e High specificity, most important marker of the early IgM response; 13 different OspC types have been described\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep31 (OspA):\u003c\/strong\u003e High specificity, seven different OspA types are known, and the OspA type determines the species\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep34 (OspB):\u003c\/strong\u003e High specificity, antibodies only appear late post-infection\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep39 (BMPA):\u003c\/strong\u003e High specificity, antibodies usually appear early post-infection\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep41 (Flagellin):\u003c\/strong\u003e Unspecific, cross-reactions with other spirochaetes and flagellated bacteria; IgM antibodies appear first and very early\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep60 (Hsp6):\u003c\/strong\u003e Unspecific, antibodies often also appear in other bacterial infections\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep66:\u003c\/strong\u003e Unspecific, antibodies common in bacterial infections\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep75 (Hsp):\u003c\/strong\u003e Unspecific\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep83\/100:\u003c\/strong\u003e High specificity, antibodies usually only in the later stage of infection\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVlsE:\u003c\/strong\u003e High specificity, IgG antibodies are possible even in the early stage; VlsE is expressed by Borrelia only in the host\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA negative serological finding does not rule out Lyme borreliosis. There may be a disease requiring treatment even without the detection of antibodies. Causes include antibiotic treatment starting early but inadequate, treatment with immunodepressants including cortisone, exhaustion of the immune system, masking of the causative agents, and genetic disposition.\u003c\/p\u003e\n\n\u003cp\u003eA positive serological finding means that the patient has acquired a Borrelia infection at some point in time. With a single serological test, it is not possible to decide whether this infection is active or latent. At best, this can be decided by the attending physician on the basis of its clinical development. It is not within the remit of a laboratory physician to evaluate a positive finding as a \"serological relic\" — that is, antibodies evidential of an earlier infection.\u003c\/p\u003e\n\n\u003ch2 id=\"csf\"\u003eExamination of Cerebrospinal Fluid (CSF)\u003c\/h2\u003e\n\n\u003cp\u003eDiagnostic testing of the cerebrospinal fluid (CSF) is indicated in cases of acute inflammation of the nervous system, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMeningitis, meningo-encephalitis, encephalomyelitis, acute encephalitis\u003c\/li\u003e\n  \u003cli\u003eAcute meningoradiculitis (Bannwarth's syndrome), Guillain-Barré syndrome\u003c\/li\u003e\n  \u003cli\u003eCerebral vasculitis, myelitis\u003c\/li\u003e\n  \u003cli\u003eNeuritis of cranial nerves, especially facial nerve paresis\u003c\/li\u003e\n  \u003cli\u003eAcute polyneuropathy\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, testing of the CSF is not indicated in the following disease states in relation to Lyme neuroborreliosis, because pathological results are not to be expected:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEncephalopathy in chronic Lyme borreliosis\u003c\/li\u003e\n  \u003cli\u003eChronic polyneuropathy in the late stage\u003c\/li\u003e\n  \u003cli\u003eCerebro-organic psychosyndrome\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePleocytosis (cell count over 5\/μL), elevated protein level, and evidence of the intrathecal synthesis of Borrelia-specific antibodies (serum\/CSF ratio) are indications of acute neuroborreliosis. However, if the neuroborreliosis occurs very soon after Borrelia infection and with late manifestations, Borrelia-specific antibodies will be absent from both the serum and the CSF, or will appear sooner in the CSF than in the serum, and vice versa.\u003c\/p\u003e\n\n\u003cp\u003eThe detection of intrathecally formed Borrelia-specific antibodies in the CSF is only very rarely possible in cases of Lyme borreliosis with neurological involvement. If acute neuroborreliosis is suspected, the treatment should not be made dependent on the laboratory results.\u003c\/p\u003e\n\n\u003ch2 id=\"ltt\"\u003eLymphocyte Transformation Test (LTT)\u003c\/h2\u003e\n\n\u003cp\u003eAs the cellular immune response (lymphocytes, monocytes) follows a more rapid dynamic than the relatively sluggish serological formation of antibodies, a lymphocyte transformation test (LTT) is faster to provide an indication of an active infection.\u003c\/p\u003e\n\n\u003cp\u003eThe following arguments support the use of cellular immunological methods in the laboratory diagnosis of Lyme borreliosis:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eThe direct identification of the causative agent is proof of Lyme borreliosis, but the sensitivity of the methods for direct identification of Borrelia is technically inadequate at present for daily practice.\u003c\/li\u003e\n  \u003cli\u003eA positive serological finding is not evidence of active Lyme borreliosis. On the other hand, a negative serological finding does not rule it out, especially when there are early manifestations of Lyme borreliosis.\u003c\/li\u003e\n  \u003cli\u003eIf there is no positive result available from a Borrelia culture or PCR for Borrelia, an LTT for Borrelia can provide an indication whether active Lyme borreliosis is present. A positive result from the LTT for Borrelia is suspicious, but not evidential, of an active Borrelia infection.\u003c\/li\u003e\n  \u003cli\u003eThe LTT for Borrelia is clearly positive even in the early stage of Borrelia infection (even if erythema migrans is present) and is generally negative or at least clearly regressive 4 to 6 weeks after the conclusion of successful antibiotic treatment.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe indications for an LTT for Borrelia are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEvidence of an active Borrelia infection in seropositive patients with ambiguous symptoms\u003c\/li\u003e\n  \u003cli\u003eA seronegative result or result assessed serologically as borderline in patients with a strong clinical suspicion of Lyme borreliosis\u003c\/li\u003e\n  \u003cli\u003eTo monitor therapy approximately 4–6 weeks after concluding a course of antibiotic treatment\u003c\/li\u003e\n  \u003cli\u003eTo monitor progress if there is a clinical suspicion of a recurrence of Lyme borreliosis\u003c\/li\u003e\n  \u003cli\u003eA new infection\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCertain laboratories offer different methods for the detection of Borrelia-specific activation of T lymphocytes, such as the EliSpot-Test-Borrelia®. In these methods, the induction of cytokine synthesis is measured at the cellular level. Although the EliSpot is well-established in the diagnosis of infectious diseases like tuberculosis, its importance in the diagnosis of borreliosis has yet to be tested by appropriate techniques.\u003c\/p\u003e\n\n\u003ch2 id=\"cd57\"\u003eCD57+ NK Cells\u003c\/h2\u003e\n\n\u003cp\u003eAccording to Stricker and Winger, CD57+ NK cells (a type of natural killer cell) are often markedly reduced in the blood of patients with chronic Lyme borreliosis. However, it is not possible to evaluate the CD57+ NK cells as a laboratory parameter in connection with Lyme borreliosis at present, on account of the insufficient data available.\u003c\/p\u003e\n\n\u003ch2 id=\"co-infections\"\u003eCo-infections\u003c\/h2\u003e\n\n\u003cp\u003eTicks can transmit multiple pathogens simultaneously, leading to co-infections that can complicate the clinical picture and treatment of Lyme borreliosis. Co-infections transmitted by ticks include various bacterial and parasitic agents that may require additional or different treatment approaches. Additionally, there are co-infections not transmitted by ticks that may be present in patients with Lyme borreliosis and should be considered in the differential diagnosis.\u003c\/p\u003e\n\n\u003ch2 id=\"antibiotic-treatment\"\u003eAntibiotic Treatment of Lyme Borreliosis\u003c\/h2\u003e\n\n\u003cp\u003eThe recommendations for antibiotic treatment presented in this guideline differ significantly in some respects from the guidelines of other specialist societies. The patient must be made aware of this fact when treated according to this guideline. In addition, careful checks for side-effects must be carried out when long-term antibiotic therapy is conducted.\u003c\/p\u003e\n\n\u003cp\u003eEarly treatment is critical. The earlier antibiotic treatment is started after infection, the better the infection can be controlled. Therapeutic success is distinctly poorer even 4 weeks after the start of infection.\u003c\/p\u003e\n\n\u003ch2 id=\"unsuitable-antibiotics\"\u003eUnsuitable Antibiotics\u003c\/h2\u003e\n\n\u003cp\u003eNot all antibiotics are effective against Borrelia bacteria. The guidelines specifically identify certain antibiotics that are unsuitable for treating Lyme borreliosis and should not be used. Patients should be aware that receiving an inappropriate antibiotic may lead to treatment failure and progression of the disease.\u003c\/p\u003e\n\n\u003ch2 id=\"suitable-antibiotics\"\u003eSuitable Antibiotics\u003c\/h2\u003e\n\n\u003cp\u003eSeveral antibiotics have been shown to be effective against Borrelia burgdorferi and related species. The choice of antibiotic depends on the stage of the disease, the organs affected, and individual patient factors. Effective antibiotics in Lyme borreliosis include specific members of the tetracycline, penicillin, and cephalosporin classes, among others.\u003c\/p\u003e\n\n\u003cp\u003eThe guidelines provide detailed tables of effective antibiotics, their dosages, and routes of administration for different clinical situations.\u003c\/p\u003e\n\n\u003ch2 id=\"monotherapy\"\u003eMonotherapy Options\u003c\/h2\u003e\n\n\u003cp\u003eFor many patients, treatment with a single antibiotic (monotherapy) may be sufficient. The guidelines provide specific recommendations for antibiotic monotherapy of Lyme borreliosis, including the drug of choice, dosage, and duration of treatment for different stages and manifestations of the disease. Early localized disease often responds well to oral antibiotics, while more advanced or neurological forms may require intravenous therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"combined-therapy\"\u003eCombined Therapy Options\u003c\/h2\u003e\n\n\u003cp\u003eIn certain situations — particularly in chronic or complicated cases — a combined therapy using two or more antibiotics may be recommended. The guidelines provide specific recommendations for antibiotics used in combined therapy of Lyme borreliosis. This approach may be considered when monotherapy has failed, in cases of co-infection, or in severe or persistent manifestations of the disease.\u003c\/p\u003e\n\n\u003ch2 id=\"prevention\"\u003ePrevention Strategies\u003c\/h2\u003e\n\n\u003cp\u003ePrevention of Lyme borreliosis focuses primarily on avoiding tick bites and removing ticks promptly when they are found. The guidelines emphasize the importance of checking for ticks after spending time in tick habitats, using appropriate protective measures, and removing attached ticks properly and quickly.\u003c\/p\u003e\n\n\u003cp\u003eAfter a tick bite, the site should be observed for 4–6 weeks for any reddening. If erythema occurs, immediate medical consultation is advised. Early antibiotic treatment at the time of erythema migrans can prevent the development of antibodies and control the infection effectively.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of Current Knowledge\u003c\/h2\u003e\n\n\u003cp\u003eDespite intensive research, there is as yet an inadequate scientific basis for the diagnosis and treatment of Lyme borreliosis. This is especially the case with the chronic forms, for which there is a lack of evidence-based studies. The guidelines acknowledge several important limitations:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTest systems for Borrelia serology are not standardised, limiting comparability between laboratories\u003c\/li\u003e\n  \u003cli\u003eDirect identification of Borrelia has poor sensitivity, especially in late manifestations\u003c\/li\u003e\n  \u003cli\u003eNegative serological findings do not rule out Lyme borreliosis\u003c\/li\u003e\n  \u003cli\u003ePositive serological findings cannot distinguish between active and latent infection\u003c\/li\u003e\n  \u003cli\u003eThe CD57+ NK cell parameter cannot be evaluated at present due to insufficient data\u003c\/li\u003e\n  \u003cli\u003eThe EliSpot test's importance in borreliosis diagnosis has yet to be tested by appropriate techniques\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese limitations mean that clinical judgment remains essential in diagnosing and treating Lyme borreliosis, particularly in its chronic forms.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this comprehensive guideline, patients should be aware of the following key recommendations:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAfter a tick bite:\u003c\/strong\u003e Observe the bite site for 4–6 weeks. If any reddening occurs, consult a doctor immediately. Consider having the tick tested for Borrelia by PCR.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf erythema migrans appears:\u003c\/strong\u003e Seek immediate antibiotic treatment. Early treatment is critical for successful outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe aware that absence of a tick bite history does not rule out Lyme disease:\u003c\/strong\u003e Up to 50% of patients do not recall a tick bite.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that negative antibody tests do not exclude Lyme disease:\u003c\/strong\u003e Especially in early stages or after early antibiotic treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRequest comprehensive testing:\u003c\/strong\u003e If Lyme borreliosis is suspected, ask for Borrelia serology including immunoblotting, not just ELISA alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider LTT testing:\u003c\/strong\u003e The lymphocyte transformation test can provide valuable information about active infection, especially when serology is inconclusive.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor occupational exposure:\u003c\/strong\u003e Document tick bites occurring during work carefully, as Lyme borreliosis is a recognized occupational disease for certain high-risk groups.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitor treatment success clinically:\u003c\/strong\u003e Serological monitoring to assess treatment success is not useful in chronic Lyme borreliosis; clinical assessment is the appropriate method.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe aware of co-infections:\u003c\/strong\u003e Ticks can transmit multiple pathogens, which may complicate diagnosis and treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss treatment options thoroughly with your physician:\u003c\/strong\u003e The recommendations in this guideline differ in some respects from other specialist societies' guidelines, and patients should be informed of these differences.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThis guideline emphasizes that Lyme borreliosis is a complex, multiorgan disease that requires careful clinical evaluation and individualized treatment. The chronic forms of the disease present particular challenges due to the lack of evidence-based studies and the limitations of current diagnostic methods.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eI had a tick bite but no rash. Can I still have Lyme disease?\u003c\/h3\u003e\n\u003cp\u003eYes. Up to 50% of Lyme disease patients do not recall a tick bite, and erythema migrans (the typical rash) is absent in up to 50% of early cases. If you have symptoms consistent with Lyme disease, such as joint pain, headache, or facial nerve palsy, discuss testing with your doctor, even without a rash.\u003c\/p\u003e\n\u003ch3\u003eMy Lyme disease antibody test was negative. Does that mean I don't have Lyme disease?\u003c\/h3\u003e\n\u003cp\u003eNo. A negative antibody test does not rule out Lyme disease. Antibodies may not appear until 2–6 weeks after infection, and early antibiotic treatment can prevent antibody development. Also, the recommended stepwise testing (ELISA first, then immunoblot) can miss up to 15% of cases. If symptoms persist, ask about immunoblot testing or a lymphocyte transformation test (LTT).\u003c\/p\u003e\n\u003ch3\u003eWhat is the lymphocyte transformation test (LTT) for Lyme disease?\u003c\/h3\u003e\n\u003cp\u003eThe LTT is a blood test that measures the cellular immune response to Borrelia. It can indicate an active infection, especially when antibody tests are negative or inconclusive. A positive LTT is suspicious but not proof of active Lyme disease. It is also used to monitor treatment success, as it usually becomes negative 4–6 weeks after successful antibiotic therapy.\u003c\/p\u003e\n\u003ch3\u003eWhat are the common symptoms of chronic Lyme disease?\u003c\/h3\u003e\n\u003cp\u003eChronic Lyme disease (manifestations lasting more than 6 months) often causes fatigue, rapid fatiguability, encephalopathy (impaired brain function), muscle and joint pain, neurological symptoms like polyneuropathy, and various skin, heart, eye, and gastrointestinal issues. Symptoms may come and go and can affect many different parts of the body.\u003c\/p\u003e\n\u003ch3\u003eCan Lyme disease be treated with antibiotics?\u003c\/h3\u003e\n\u003cp\u003eYes. Early antibiotic treatment is very effective. The guidelines recommend specific antibiotics (e.g., tetracyclines, penicillins, cephalosporins) for different stages. For chronic cases, long-term antibiotic therapy may be recommended, but this differs from other guidelines. Always discuss treatment options with your doctor, as the choice depends on the stage and organs affected.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Diagnosis and Treatment of Lyme borreliosis Guidelines\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Deutsche Borreliose-Gesellschaft e. V. (German Borreliosis Society)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication Details:\u003c\/strong\u003e Revised 2nd edition, December 2010 (1st edition finalised April 2008)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Deutsche Borreliose-Gesellschaft e. V., Am Planetarium 12, D-07743 Jena, Germany\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research and clinical guidelines. The original guideline was prepared with great care, but no liability can be accepted for its accuracy, especially in relation to dosages, either by the authors or by the German Borreliosis Society. Patients should always consult with their healthcare provider regarding diagnosis and treatment decisions.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47457931919516,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com.br\/products\/understanding-lyme-disease-a-complete-guide-to-diagnosis-and-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}